AI Article Synopsis
Article Abstract
Background: The development of protocols for the ex vivo generation of dendritic cells (DCs) has led to intensive research into their potential use in immunotherapy in the treatment of cancer. In this study, we examined the efficacy of dendritic cell-tumor cell fusion hybrid vaccines in eliciting an immune response against Lewis lung carcinoma (LLC) cells, as compared to other types of tumor vaccines. In addition, we also tested whether the efficacy of the vaccines was affected by the route of administration. Four different tumor vaccines were compared: (1) HC (hybrid cell), consisting of DC/LLC hybrids; (2) DC+LLC (DCs pulsed with apoptotic LLCs); (3) DC without antigen loading/pulsing; (4) LLC (apoptotic/irradiated tumor cells). We also compared four different routes of administration for each vaccine: (1) Preimmunization; (2) Vaccination therapy; (3) Adoptive immunotherapy; (4) Vaccination therapy combined with adoptive immunotherapy. Anti-tumor immunity was assessed in vivo and the CTL (cytotoxic T lymphocyte) response as well as the expression of key cytokines, IFN-γ and IL-10 were further evaluated using in vitro assays.
Results: Our data demonstrate that vaccination with HC hybrids provides more effective anti-tumor protective immunity and significantly greater therapeutic immunity than vaccination with DC+LLC, DC or LLC. Most remarkably, vaccination therapy with HC hybrids was more successful than combination (vaccination + adoptive) therapy for the induction of anti-tumor responses. Splenocytes harvested from mice immunized with HC hybrids demonstrated the greatest cytotoxic T lymphocyte (CTL) activity and their production of IFN-γ was high, while their production of IL-10 was very low.
Conclusions: Our results suggest that vaccination therapy with DC-tumor cell fusion hybrids provides more effective protection against lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08916934.2013.850080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cancer vaccines: an update on recent achievements and prospects for cancer therapy.
Clin Exp Med
December 2024
Department of Virology, National Institute of Public Health NIH-National Research Institute, Warsaw, Poland.
Decades of basic and translational research have led to a momentum shift in dissecting the relationship between immune cells and cancer. This culminated in the emergence of breakthrough immunotherapies that paved the way for oncologists to manage certain hard-to-treat cancers. The application of high-throughput techniques of genomics, transcriptomics, and proteomics was conclusive in making and expediting the manufacturing process of cancer vaccines.
View Article and Find Full Text PDFImprovements of acute flaccid paralysis and measles surveillance performances in response to outbreak of circulating vaccine-derived poliovirus (2021-2022): the case of Southwest Ethiopia Region, Ethiopia.
Pan Afr Med J
December 2024
World Health Organization, Expanded Programme on Immunization, Maternal Child Health and Nutrition, Addis Ababa, Ethiopia.
Introduction: following the detection of vaccine-derived poliovirus in 2019 in Ethiopia, response activities have been conducted including strengthening disease surveillance activities.
Methods: trend analysis study design of acute flaccid paralysis and measles surveillance data for the years 2021 and 2022 for Southwest Ethiopia Region was used. The non-polio acute flaccid paralysis (AFP) rate and stool adequacy rates were used to assess the AFP surveillance.
"Are we ready to transition from the Global Alliance for Vaccines and Immunization support?" Perceptions from 15 Kenyan counties.
Pan Afr Med J
December 2024
Division of Population Health, Sheffield Centre for Health and Related Research, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.
Introduction: Gavi, the Vaccine Alliance, defined a transition roadmap for countries receiving funding support based on their income status projections. According to the latest projections, Kenya will complete their transition from vaccine funding in 2029. While eligible countries are kept informed and supported for a smooth transition process, the extent to which countries understand the significant implications of a complete end of GAVI support on immunization service delivery varies.
View Article and Find Full Text PDFOral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study.
eNeurologicalSci
March 2025
Department of Internal Medicine, Miwa Naika Clinic, Toyama, Japan.
Background: Myalgic encephalomyelitis (ME) is associated with long COVID and also untoward sequelae after anti-coronavirus vaccination. Recently, oral minocycline therapy has been reported to ameliorate symptoms in patients with ME, particularly at the initial stage of the disease.
Methods: Oral minocycline (100 mg × 2 on the first day, followed by 100 mg/day for 41 days) was administered to 55 patients with ME that emerged during the "Corona era," including 19 patients with long COVID and 5 patients diagnosed with untoward sequalae following coronavirus vaccination.
Case Reports: Chemokine and Cytokine Profiling in Patients with Herpetic Uveitis.
Int Med Case Rep J
December 2024
Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE, USA.
Purpose: To report cytokine/chemokine profiles of ocular fluid in two patients with herpetic uveitis.
Methods: Cytokine and chemokine profiling of ocular fluid was performed in two patients with herpetic uveitis. Ocular fluid findings were correlated with disease manifestations and the patients' clinical course.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!